AnjaliSAdvaniMD

Hematologic Oncology

Director, Inpatient Leukemia Unit, Cleveland Clinic Taussig Cancer Institute Professor of Medicine, Cleveland Clinic Lerner College of Medicine

Join to view full profile

Dr. Advani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Advani's full profile

Already have an account?

Office
10201 Carnegie Avenue
Desk CA60
Cleveland, OH 44195
Phone+1 216-445-9354

Fax+1 216-444-9464

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1999 - 2002
Duke University HospitalResidency, Internal Medicine, 1996 - 1999
Duke University School of MedicineClass of 1996

Certifications & Licensure

OH State Medical License 2002 - 2025
NC State Medical License 1997 - 2003
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia Start of enrollment: 2003 Jul 01
Completed
Phase 1
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia Start of enrollment: 2006 Jan 01
Terminated
Phase 2
S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2006 Oct 01
Completed
Phase 2
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens Start of enrollment: 2006 Jul 01
Terminated
Phase 2
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy Start of enrollment: 2008 Oct 01
Completed
Phase 2
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
Active, not recruiting
Phase 2
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
Completed
Phase 2
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia Start of enrollment: 2009 Dec 10
Completed
Phase 2
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2010 Sep 01
Completed
Phase 2
S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia Start of enrollment: 2010 Jun 01
Completed
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2010 Jul 01
Completed
Phase 1
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
A Safety Study of SGN-CD33A in AML Patients Start of enrollment: 2013 Jul 01
Completed
Phase 1
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia Start of enrollment: 2014 Jun 13
Completed
Phase 1
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Oct 08
Completed
Phase 1
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia Start of enrollment: 2015 Jun 30
Active, not recruiting
Phase 2
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) Start of enrollment: 2021 Feb 08
Recruiting
Phase 2
Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML Start of enrollment: 2021 Jul 12
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML Start of enrollment: 2023 Jul 18
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

849 citations
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes, Giovanni Martinelli, Michaela Liedtke
The New England Journal of Medicine. 2016-06-12
3 citations
Novel strategies in the treatment of acute lymphoblastic leukaemia.
Anjali S Advani
The Lancet. Haematology. 2022-04-01
37 citations
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
Caner Saygin, Ashwin Kishtagari, Ryan D. Cassaday, Natalie Reizine, Ilana R. Yurkiewicz
Blood Advances. 2019-12-23

Journal Articles

A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML
Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Abstracts/Posters

Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Ov...
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Determinants of Fitness for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving I...
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and My...
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoie...
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of CancerClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with N...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Analysis from INO-VATE by bone marrow blast percen...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

Ponatinib Linked with Better Outcomes Than Imatinib in Philadelphia Chromosome-Positive ALLMarch 17th, 2023
New Treatment Combination Without Chemotherapy Is Effective in PH+ Acute Lymphoblastic LeukemiaDecember 13th, 2021
Addition of Ixazomib to MEC Chemotherapy Promising in R/R AMLAugust 30th, 2019
Join now to see all